Adriamycin
Epstein-Barr Virus-Associated Lymphoproliferative Disorder
Explore 8 assets in Epstein-Barr Virus-Associated Lymphoproliferative Disorder →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
University of Miami
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epstein-Barr Virus-Associated Lymphoproliferative Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | University of Miami | P2 | CCC · 53 |
| Tabelecleucel | Pierre Fabre Medicament | P3 | BB |
| Valganciclovir | Viracta Therapeutics, Inc. | P2 | B |
| Arginine Butyrate | HemaQuest Pharmaceuticals Inc. | P2 | CCC |
| Hydroxyurea | University of Miami | P2 | CCC |
| Ganciclovir | HemaQuest Pharmaceuticals Inc. | P2 | CCC |
| Rituximab | University of Miami | P2 | CCC |
| Retrovir | University of Miami | P2 | CCC |
| Ebv-Specific T Cells: B | Ciusss de L'Est de l'Île de Montréal | P2 | CCC |
+9 more in the Epstein-Barr Virus-Associated Lymphoproliferative Disorder cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Epstein-Barr Virus-Associated Lymphoproliferative Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-epstein-barr-virus-associated-lymphoproliferative-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →